Akero Therapeutics (NASDAQ:AKRO) Releases Earnings Results, Misses Estimates By $0.15 EPS

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.15), Briefing.com reports.

Akero Therapeutics Stock Performance

NASDAQ:AKRO traded down $1.41 on Monday, hitting $33.04. 609,746 shares of the company's stock traded hands, compared to its average volume of 550,346. The firm has a 50-day moving average price of $29.02 and a 200-day moving average price of $25.27. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04. Akero Therapeutics has a 1 year low of $13.47 and a 1 year high of $37.00.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Akero Therapeutics in a report on Monday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Akero Therapeutics has an average rating of "Moderate Buy" and an average price target of $43.20.

Insider Buying and Selling at Akero Therapeutics

In related news, insider Catriona Yale sold 8,851 shares of Akero Therapeutics stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $27.53, for a total transaction of $243,668.03. Following the completion of the sale, the insider now owns 75,931 shares of the company's stock, valued at approximately $2,090,380.43. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Catriona Yale sold 8,851 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $27.53, for a total transaction of $243,668.03. Following the transaction, the insider now owns 75,931 shares in the company, valued at $2,090,380.43. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Andrew Cheng sold 1,738 shares of Akero Therapeutics stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $26.18, for a total transaction of $45,500.84. Following the completion of the sale, the chief executive officer now directly owns 605,417 shares of the company's stock, valued at approximately $15,849,817.06. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 428,397 shares of company stock worth $12,997,971. 7.94% of the stock is currently owned by company insiders.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.